What question did this study set out to answer?

To evaluate the effect of corticosteroid premedication on toxicity and survival rates in patients treated with enfortumab vedotin for urothelial carcinoma.

March 25, 2026International Journal of Urology1 citations

View Full Paper

Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

MSMasanao ShinoharaHirosaki University HYHayato YamamotoHirosaki University YKYohei KawashimaHakodate Central General Hospital

Key Points

To evaluate the effect of corticosteroid premedication on toxicity and survival rates in patients treated with enfortumab vedotin for urothelial carcinoma.
Conducted an observational study of patients receiving enfortumab vedotin.
Analyzed the correlation between corticosteroid premedication and reported skin toxicities.
Monitored survival outcomes in relation to premedication use.
Corticosteroid premedication significantly reduced skin toxicities during treatment.
Survival impact of corticosteroid premedication remains uncertain and needs further validation.

Abstract

Corticosteroid premedication reduces skin toxicities during EV monotherapy, but its impact on survival remains uncertain and requires validation in larger studies.

问 AI

Bookmark

View Full Paper

Cite This Study

Shinohara et al. (Sun,) studied this question.

synapsesocial.com/papers/69c37bd4b34aaaeb1a67e8bf https://doi.org/https://doi.org/10.1111/iju.70425

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

问 AI

Bookmark

View Full Paper